118 related articles for article (PubMed ID: 35131083)
1. STK11 Loss: A Novel Mechanism for Melanoma Metastasis with Therapeutic Implications.
Azin M; Demehri S
J Invest Dermatol; 2022 Apr; 142(4):1007-1009. PubMed ID: 35131083
[TBL] [Abstract][Full Text] [Related]
2. STK11 Prevents Invasion through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma.
Dzung A; Saltari A; Tiso N; Lyck R; Dummer R; Levesque MP
J Invest Dermatol; 2022 Apr; 142(4):1171-1182.e10. PubMed ID: 34757069
[TBL] [Abstract][Full Text] [Related]
3. STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma.
Momtaz S; Niaz K; Maqbool F; Abdollahi M; Rastrelli L; Nabavi SM
Biofactors; 2017 May; 43(3):347-370. PubMed ID: 27896891
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis.
Huang FJ; Steeg PS; Price JE; Chiu WT; Chou PC; Xie K; Sawaya R; Huang S
Cancer Res; 2008 Dec; 68(23):9634-42. PubMed ID: 19047140
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma.
Wu ZS; Cheng XW; Wang XN; Song NJ
Melanoma Res; 2011 Dec; 21(6):483-90. PubMed ID: 21876460
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.
Vultur A; Villanueva J; Krepler C; Rajan G; Chen Q; Xiao M; Li L; Gimotty PA; Wilson M; Hayden J; Keeney F; Nathanson KL; Herlyn M
Oncogene; 2014 Apr; 33(14):1850-61. PubMed ID: 23624919
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of STAT3 targets a subpopulation of invasive melanoma stem-like cells.
Kulesza DW; Przanowski P; Kaminska B
Cell Biol Int; 2019 Jun; 43(6):613-622. PubMed ID: 30958597
[TBL] [Abstract][Full Text] [Related]
8. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
9. MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression.
Yang W; Khoury E; Guo Q; Prabhu SA; Emond A; Huang F; Gonçalves C; Zhan Y; Plourde D; Nichol JN; Dahabieh MS; Miller WH; Del Rincón SV
Oncogene; 2020 Apr; 39(18):3650-3665. PubMed ID: 32132651
[TBL] [Abstract][Full Text] [Related]
10. Pseudopodium enriched atypical kinase 1(PEAK1) promotes invasion and of melanoma cells by activating JAK/STAT3 signals.
Pan M; Yin X; Huang YC
Bioengineered; 2021 Dec; 12(1):5045-5055. PubMed ID: 34365903
[TBL] [Abstract][Full Text] [Related]
11. Focal adhesion kinase promotes the aggressive melanoma phenotype.
Hess AR; Postovit LM; Margaryan NV; Seftor EA; Schneider GB; Seftor RE; Nickoloff BJ; Hendrix MJ
Cancer Res; 2005 Nov; 65(21):9851-60. PubMed ID: 16267008
[TBL] [Abstract][Full Text] [Related]
12. Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation.
Liu J; Qu X; Shao L; Hu Y; Yu X; Lan P; Guo Q; Han Q; Zhang J; Zhang C
Cancer Biol Ther; 2018 Mar; 19(3):160-168. PubMed ID: 29370558
[TBL] [Abstract][Full Text] [Related]
13. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J; Chevret S; Jouary T; Dalac S; Dalle S; Guillot B; Arnault JP; Avril MF; Bedane C; Bens G; Pham-Ledard A; Mansard S; Grange F; Machet L; Meyer N; Legoupil D; Saiag P; Idir Z; Renault V; Deleuze JF; Hindie E; Battistella M; Dumaz N; Mourah S; Lebbe C;
J Invest Dermatol; 2018 Jan; 138(1):58-67. PubMed ID: 28843487
[TBL] [Abstract][Full Text] [Related]
14. MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2.
Hu Y; Wang Q; Zhu XH
Melanoma Res; 2019 Apr; 29(2):119-125. PubMed ID: 30480622
[TBL] [Abstract][Full Text] [Related]
15. Artesunate inhibits melanoma progression in vitro via suppressing STAT3 signaling pathway.
Berköz M; Özkan-Yılmaz F; Özlüer-Hunt A; Krośniak M; Türkmen Ö; Korkmaz D; Keskin S
Pharmacol Rep; 2021 Apr; 73(2):650-663. PubMed ID: 33609273
[TBL] [Abstract][Full Text] [Related]
16. Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional
Pore N; Wu S; Standifer N; Jure-Kunkel M; de Los Reyes M; Shrestha Y; Halpin R; Rothstein R; Mulgrew K; Blackmore S; Martin P; Meekin J; Griffin M; Bisha I; Proia TA; Miragaia RJ; Herbst R; Gupta A; Abdullah SE; Raja R; Frigault MM; Barrett JC; Dennis PA; Ascierto ML; Oberst MD
Cancer Discov; 2021 Nov; 11(11):2828-2845. PubMed ID: 34230008
[TBL] [Abstract][Full Text] [Related]
17. SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.
Hüser L; Sachindra S; Granados K; Federico A; Larribère L; Novak D; Umansky V; Altevogt P; Utikal J
Int J Cancer; 2018 Dec; 143(12):3131-3142. PubMed ID: 29905375
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target.
Villares GJ; Zigler M; Bar-Eli M
Oncotarget; 2011; 2(1-2):8-17. PubMed ID: 21378407
[TBL] [Abstract][Full Text] [Related]
19. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases.
Kreis S; Munz GA; Haan S; Heinrich PC; Behrmann I
Mol Cancer Res; 2007 Dec; 5(12):1331-41. PubMed ID: 18171991
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the STAT3 signaling pathway contributes to apigenin-mediated anti-metastatic effect in melanoma.
Cao HH; Chu JH; Kwan HY; Su T; Yu H; Cheng CY; Fu XQ; Guo H; Li T; Tse AK; Chou GX; Mo HB; Yu ZL
Sci Rep; 2016 Feb; 6():21731. PubMed ID: 26911838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
